---
title: "Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290311012.md"
description: "New clinical data has shown positive proof-of-concept results for OD-001 in a Phase 2a trial focusing on treating moderate to severe cases of ulcerative colitis. This promising development showcases the effectiveness of OD-001 as a monotherapy in addressing the condition. The specific numbers regarding the success rates and improvements observed in patients have not been disclosed."
datetime: "2026-06-19T21:23:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290311012.md)
  - [en](https://longbridge.com/en/news/290311012.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290311012.md)
---

# Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

New clinical data has shown positive proof-of-concept results for OD-001 in a Phase 2a trial focusing on treating moderate to severe cases of ulcerative colitis. This promising development showcases the effectiveness of OD-001 as a monotherapy in addressing the condition. The specific numbers regarding the success rates and improvements observed in patients have not been disclosed.

### Related Stocks

- [ODTX.US](https://longbridge.com/en/quote/ODTX.US.md)

## Related News & Research

- [Eupraxia posts corporate presentation detailing RESOLVE trial symptom response data](https://longbridge.com/en/news/295794647.md)
- [Yalla’s Bet On New Mid-And Hardcore Gaming Titles Pays Off](https://longbridge.com/en/news/296504966.md)
- [Sagimet wins FDA IND clearance for Phase 3 denifanstat acne trial](https://longbridge.com/en/news/295786871.md)
- [Sagimet Biosciences Gets FDA Clearance For Phase 3 Acne Study](https://longbridge.com/en/news/295789901.md)
- [Definium Therapeutics publishes corporate presentation outlining DT120 ODT clinical development pipeline in mental health indications](https://longbridge.com/en/news/295840904.md)